Delivery Order SPE2DB20D2002-SPE2DB23FL65C
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,654.52 firm fixed-price delivery order is for the supply of Ondansetron ODT 8 mg tablets, a medication used to prevent nausea and vomiting. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,791.65 firm-fixed-price delivery order is for the supply of Ondansetron ODT 4 mg tablets, a medication used to prevent nausea and vomiting. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,491.43 firm-fixed-price delivery order is for the supply of 4 mg Ondansetron HCL tablets, a medication used to prevent nausea and vomiting. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award, valued at $17,396.42, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ondansetron ODT 8 mg tablets in 30-count packages, which are used to treat nausea and vomiting. The contract is a Firm Fixed Price Delivery Order that does not have any set-aside designation, indicating open competition. AmerisourceBergen holds a significant...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $1,608.63 delivery order contract is for the provision of Ondansetron ODT 8 mg tablets, a medication used to prevent nausea and vomiting. The contract has an ultimate completion date of December 28, 2023 and is a Firm Fixed Price arrangement. AmerisourceBergen also holds a $999,999,999 Indefinite Delivery...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,934.51 firm-fixed-price delivery order is for the supply of 4,566,666,962 tablets of Ondansetron ODT 8 mg, a medication used to prevent nausea and vomiting. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support...
- This federal contract award, valued at $9,169.91, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ondansetron ODT 8 mg tablets, a medication used to treat nausea and vomiting. The award is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,910.38 firm fixed-price contract is for the delivery of Ondansetron ODT 4 mg tablets, a medication used to prevent nausea and vomiting. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $19,558.29 firm fixed-price delivery order is for the supply of 4566809747 - Ondansetron ODT 8 mg tablets, a medication used to treat nausea and vomiting. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,520.12 fixed-price delivery order is for the supply of 4,563,068,942 units of Ondansetron HCL 8 mg tablets, a medication used to prevent nausea and vomiting. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical...
- SPE2DB20D2002Indefinite Delivery Contract
- SPE2DB20D2002-SPE2DB23FL65CDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,793.05 Delivery Order contract is for the supply of Ondansetron ODT 8 mg tablets, a medication used to treat nausea and vomiting. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This IDC encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The contract award does not have a set-aside designation, indicating open competition. AmerisourceBergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.8k | 8/25/23 |